The QEAN Blog
And we were just getting used to ICD-10.
First genetically-engineered immunotherapy approved by the FDA.
Dashboards include data for Medicare Part B, Medicare Part D, and Medicaid.
Pharmaceutical manufacturers, pharmacy benefits managers and insurers square off.
If the new rules make it through the comment period, patients, acute and long term care hospitals, and certain out-of-network specialists will see big changes.
“To become comfortable with uncertainty is one of the primary goals in the training of a physician.”
At the corner of pharma and technology – the future of product development?
Major drivers are prices of labor and goods, and administrative costs.
Ending tax breaks to oil and gas companies would replace the lost tax revenue.
They know it’s a problem, just not a high priority.
Building better circuitry with bacteria.
Designed to curb unproven and unsafe practices.
The systematic study of “X-radiation” was an important milestone on the path to developing valuable medical diagnostics and therapies.
A shorter questionnaire may be a better questionnaire.
A reminder to stay on top of how pending healthcare rules and regulations may impact your customers.
Pharma is all in, and medical device companies need to jump on board to investigate ways to leverage this new application of biotechnology.
What 14 German sponges can teach us about research and publicity.
Artificial intelligence is here, and it's here to stay.
Blockchain is about to become a Big Deal, and companies that waffle may regret their indecisiveness.
As a manufacturer, a hospital, a laboratory or a patient, a drone might be in your future.
Not legally enforceable, but stakeholders should still address cyber vulnerabilities.
Supply chain automation can yield benefits in unexpected areas.
Understanding each methodology’s strengths and weaknesses will help you select the right technique.